

27 May 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/foresee-pharmaceuticals-announces-completion-of-casppian-phase-3-study-with-last-patient-last-visit-and-confirms-topline-results-94-of-patients-achieve-lh-suppression-with-6-month-dosing-interval-of-leuprolide-mesylate-also-the-acceptance-o-876374774.html